<DOC>
	<DOCNO>NCT01306461</DOCNO>
	<brief_summary>The purpose study compare efficacy safety preservative-free fixed-dose combination tafluprost timolol ( FDC ) concomitant administration tafluprost timolol . This study enroll patient ocular hypertension glaucoma . The study schedule include seven visit study site three stage : - washout 5 day 4 week depend current glaucoma medication ( ) - 6-month study treatment period - 1-3 week post-study period</brief_summary>
	<brief_title>Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Aged 18 year A diagnosis ocular hypertension openangle glaucoma Meet specific IOP level visit 1 ( screen ) visit 2 ( baseline ) Meet specific visual acuity score Are willing follow instruction Have provide write informed consent Females pregnant , nurse plan pregnancy IOP great 36 mmHg time point screen baseline Diagnosis angleclosure glaucoma secondary glaucoma capsular pigmentary glaucoma either eye Suspected contraindication hypersensitivity study medication tafluprost timolol ( e.g . asthma , low pulse ) washout medication brinzolamide Glaucoma filtration surgery ocular surgery ( include ocular laser procedure ) within 6 month prior Screening Use contact lenses Screening study Presence abnormality significant illness could expect interfere patient safety study parameter Current participation another clinical trial within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>